|
1
|
He Q, Chen Z, Cabay RJ, Zhang L, Luan X,
Chen D, Yu T, Wang A and Zhou X: microRNA-21 and microRNA-375 from
oral cytology as biomarkers for oral tongue cancer detection. Oral
Oncol. 57:15–20. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu W, Zhao X, Zhang YJ, Fang GW and Xue
Y: MicroRNA-375 as a potential serum biomarker for the diagnosis,
prognosis, and chemosensitivity prediction of osteosarcoma. J Int
Med Res. 46:975–983. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mao L, Li J, Chen WX, Cai YQ, Yu DD, Zhong
SL, Zhao JH, Zhou JW and Tang JH: Exosomes decrease sensitivity of
breast cancer cells to adriamycin by delivering microRNAs. Tumour
Biol. 37:5247–5256. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu DD, Wu Y, Zhang XH, Lv MM, Chen WX,
Chen X, Yang SJ, Shen H, Zhong SL, Tang JH, et al: Exosomes from
adriamycin-resistant breast cancer cells transmit drug resistance
partly by delivering miR-222. Tumour Biol. 37:3227–3235. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dundar HA, Kiray M, Kir M, Kolatan E,
Bagriyanik A, Altun Z, Aktas S, Ellidokuz H, Yilmaz O, Mutafoglu K,
et al: Protective effect of acetyl-L-carnitine against
doxorubicin-induced cardiotoxicity in wistar albino rats. Arch Med
Res. 47:506–514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McCreight LJ, Bailey CJ and Pearson ER:
Metformin and the gastrointestinal tract. Diabetologia. 59:426–435.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang J, Wei D, Wang W, Shen B, Xu S and
Cao Y: TRAF4 enhances oral squamous cell carcinoma cell growth,
invasion and migration by Wnt-β-catenin signaling pathway. Int J
Clin Exp Pathol. 8:11837–11846. 2015.PubMed/NCBI
|
|
9
|
Fan C, Wang Y, Liu Z, Sun Y, Wang X, Wei G
and Wei J: Metformin exerts anticancer effects through the
inhibition of the Sonic hedgehog signaling pathway in breast
cancer. Int J Mol Med. 36:204–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Wang Z, Zhao X, Ji N, Zhou Y and
Li J: The inhibitory effect of metformin on oral squamous cell
carcinoma. Zhonghua Kou Qiang Yi Xue Za Zhi. 50:360–365. 2015.(In
Chinese). PubMed/NCBI
|
|
11
|
Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and
Pan Y: In vitro and in vivo antitumoral action of metformin on
hepatocellular carcinoma. Hepatol Res. 42:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cui R, Yue W, Lattime EC, Stein MN, Xu Q
and Tan XL: Targeting tumor-associated macrophages to combat
pancreatic cancer. Oncotarget. 7:50735–50754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu JC, Sopka DS, Mehra R, Lango MN,
Fundakowski C, Ridge JA and Galloway TJ: Early oral tongue cancer
initially managed with surgery alone: Treatment of recurrence.
World J Otorhinolaryngol Head Neck Surg. 2:193–197. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ,
Gutkind JS, Kulkarni AB and Sun ZJ: PD-1 blockade attenuates
immunosuppressive myeloid cells due to inhibition of CD47/SIRPα
axis in HPV negative head and neck squamous cell carcinoma.
Oncotarget. 6:42067–42080. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai WX, Yu RQ, Ma L, Huang HZ, Zheng LW
and Zwahlen R: Differences between epithelial and mesenchymal human
tongue cancer cell lines in experimental metastasis. Oncol Lett.
15:9959–9964. 2018.PubMed/NCBI
|
|
17
|
Jung HM, Benarroch Y and Chan EK:
Anti-cancer drugs reactivate tumor suppressor miR-375 expression in
tongue cancer cells. J Cell Biochem. 116:836–843. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rogulj D, El Aklouk I, Konjevoda P, Ljubić
S, Pibernik Okanović M, Barbir A, Luburić M, Radman M, Budinski N
and Vučić Lovrenčić M: Age-dependent systemic DNA damage in early
Type 2 Diabetes mellitus. Acta Biochim Pol. 64:233–238. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Merino J, Leong A, Liu CT, Porneala B,
Walford GA, von Grotthuss M, Wang TJ, Flannick J, Dupuis J, Levy D,
et al: Metabolomics insights into early type 2 diabetes
pathogenesis and detection in individuals with normal fasting
glucose. Diabetologia. 61:1315–1324. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J and Zhang Y, Tan X, Zhang Q, Liu C
and Zhang Y: MiR-23b-3p induces the proliferation and metastasis of
esophageal squamous cell carcinomas cells through the inhibition of
EBF3. Acta Biochim Biophys Sin (Shanghai). 50:605–614. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kabel AM, Omar MS, Balaha MF and Borg HM:
Effect of metformin and adriamycin on transplantable tumor model.
Tissue Cell. 47:498–505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bao B, Wang Z, Ali S, Ahmad A, Azmi AS,
Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, et al: Metformin
inhibits cell proliferation, migration and invasion by attenuating
CSC function mediated by deregulating miRNAs in pancreatic cancer
cells. Cancer Prev Res (Phila). 5:355–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miao L, Guo S, Lin CM, Liu Q and Huang L:
Nanoformulations for combination or cascade anticancer therapy. Adv
Drug Deliv Rev. 115:3–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
